Malaria vaccine

Jindal, Harashish; Bhatt, Bhumika; Malik, JS; Sk, Shashikantha; Mehta, Bharti

doi:10.4161/hv.28482

Cited by 4 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early success with RTS,S led to reduced priority for, and less funding being directed at vaccines targeting blood-stage malaria, delaying vaccine development for infection by parasites at this stage. However, once RTS,S was found to have poor immunogenicity in women and children and increased pediatric morbidity, research interest in blood-stage malaria vaccines significantly intensified [ 30 , 113 , 114 ].…”

Section: Recent Clinical Trials Challenges and Prospectsmentioning

confidence: 99%

Progress in the Development of Subunit Vaccines against Malaria

et al. 2020

View full text Add to dashboard Cite

Malaria is a life-threatening disease and one of the main causes of morbidity and mortality in the human population. The disease also results in a major socio-economic burden. The rapid spread of malaria epidemics in developing countries is exacerbated by the rise in drug-resistant parasites and insecticide-resistant mosquitoes. At present, malaria research is focused mainly on the development of drugs with increased therapeutic effects against Plasmodium parasites. However, a vaccine against the disease is preferable over treatment to achieve long-term control. Trials to develop a safe and effective immunization protocol for the control of malaria have been occurring for decades, and continue on today; still, no effective vaccines are available on the market. Recently, peptide-based vaccines have become an attractive alternative approach. These vaccines utilize short protein fragments to induce immune responses against malaria parasites. Peptide-based vaccines are safer than traditional vaccines, relatively inexpensive to produce, and can be composed of multiple T- and B-cell epitopes integrated into one antigenic formulation. Various combinations, based on antigen choice, peptide epitope modification and delivery mechanism, have resulted in numerous potential malaria vaccines candidates; these are presently being studied in both preclinical and clinical trials. This review describes the current landscape of peptide-based vaccines, and addresses obstacles and opportunities in the production of malaria vaccines.

show abstract

Section: Recent Clinical Trials Challenges and Prospectsmentioning

confidence: 99%

Progress in the Development of Subunit Vaccines against Malaria

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Son yıllarda yoğun aşı çalışmaları olmasına karşın henüz klinik kullanıma girebilmiş etkili bir aşı bulunmamaktadır. Ancak yeni teknoloji ürünleri olan DNA bazlı aşıların faz çalışmaları gelecek için umut vermektedir (26,27).…”

Section: İrdelemeunclassified

Imported Malaria Caused by Plasmodium falciparum: A Global Problem

Başaran¹,

Şimşek-Yavuz²,

Çağatay³

et al. 2017

Klimik Dergisi

View full text Add to dashboard Cite

Objective: Plasmodium falciparum acquired abroad, has become the main causative malaria agent in Turkey due to the elimination of endemic P. vivax in recent years. By describing clinical, laboratory and treatment features of imported malaria cases caused by P. falciparum, we aimed to distinguish it from other infectious diseases with similar epidemiological and clinical features, such as viral haemorrhagic fevers, and therefore to ensure the recognition of this kind of deadly malaria earlier.Methods: All cases hospitalized in Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University with a diagnosis of malaria between 2000 and 2016 were included in the study. Epidemiological, clinical, laboratory features and antimalarial drugs used either for prophylaxis or treatment of the cases were retrieved from the hospital database retrospectively. Results: A total of 16 patients diagnosed as having malaria caused by P. falciparum were followed our clinic during the study period. Apart from one patient who had visited Afghanistan, all of the cases acquired the infection during an Africa visit. Except two patients who received irregular prophylaxis, none of the patients had used prophylactic drugs for prevention of malaria. All of the patients had fever and shaking chills. The most frequently encountered pathologic laboratory findings were thrombocytopenia and elevated serum LDH levels. Of the patients, 50% had severe malaria and 31% were followed in intensive care unit. Artemether-lumefantrine was the most frequent (44%) regimen for treatment. All patients were discharged with full recovery except one lost due to cerebral malaria. Conclusions: Patients who acquired malaria abroad are most likely to acquire a more severe form of the disease because of the lack of the antibodies resulting from previous exposure. To avoid this severe disease, it is important to give more attention to appropriate prophylaxis against malaria among persons who plan to visit endemic areas. Klimik Dergisi 2017; 30(3): 120-5.

show abstract

“…However, there are several reasons to reevaluate the use of radiated inactivation and attenuation for the production of vaccines [ 20 21 ]. The recent successful development of irradiated vaccines for human malaria and influenza have demonstrated the feasibility and practicality of this technique, and have shown that technical problems can be overcome using existing expertise, without needing to resort to sophisticated technology [ 22 23 ]. Moreover, this technology has been used to produce an anti-cancer vaccine by inactivating cancer cells [ 24 25 26 ].…”

Section: Radiation and Vaccinesmentioning

confidence: 99%

“…Of these, P. falciparum is responsible for 92% of deaths that mostly occur in children living in sub-Saharan Africa [ 125 ]. In 2012 there was an estimated 220 million clinical cases and 0.63 million deaths worldwide from malaria infection [ 23 ]. An effective vaccine for P. falciparum is needed for use in malaria-endemic populations, but no licensed malaria vaccines and candidates have consistently produced a protective level of efficacy [ 126 ].…”

Section: Irradiated Malaria Vaccinesmentioning

confidence: 99%

Application of radiation technology in vaccines development

Seo

2015

Clin Exp Vaccine Res

View full text Add to dashboard Cite

One of the earliest methods used in the manufacture of stable and safe vaccines is the use of chemical and physical treatments to produce inactivated forms of pathogens. Although these types of vaccines have been successful in eliciting specific humoral immune responses to pathogen-associated immunogens, there is a large demand for the development of fast, safe, and effective vaccine manufacturing strategies. Radiation sterilization has been used to develop a variety of vaccine types, because it can eradicate chemical contaminants and penetrate pathogens to destroy nucleic acids without damaging the pathogen surface antigens. Nevertheless, irradiated vaccines have not widely been used at an industrial level because of difficulties obtaining the necessary equipment. Recent successful clinical trials of irradiated vaccines against pathogens and tumors have led to a reevaluation of radiation technology as an alternative method to produce vaccines. In the present article, we review the challenges associated with creating irradiated vaccines and discuss potential strategies for developing vaccines using radiation technology.

show abstract

Malaria vaccine

Cited by 4 publications

References 6 publications

Progress in the Development of Subunit Vaccines against Malaria

Progress in the Development of Subunit Vaccines against Malaria

Imported Malaria Caused by Plasmodium falciparum: A Global Problem

Application of radiation technology in vaccines development

Contact Info

Product

Resources

About